



Date: 23 April 2019

Sydney, Australia

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office  
and**

**Operational Office:**

Suite 3, Level 4

828 Pacific Highway

Gordon NSW 2072

Australia

**Board of Directors**

**Dr Graham Kelly**

Executive Chairman

**Mr Peter Marks**

Deputy Chairman

Non-Executive Director

**Dr Ian Dixon**

Non-Executive Director

**Mr John Moore**

Non-Executive Director

**Chief Executive Officer  
and Chief Medical Officer**

Dr Greg van Wyk

**Chief Financial Officer**

Shawn Van Boheemen

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## Change in Noxopharm Limited Board Structure

- **Dr Graham Kelly appointed Executive Chairman**
- **Mr Peter Marks appointed Non-Executive Deputy Chairman**
- **Dr Beata Niechoda appointed Special Advisor to the Board**

**SYDNEY, April 23, 2019:** Noxopharm (ASX: NOX) ('Noxopharm' or the 'Company') announces a number of Board changes.

Graham Kelly moves from Group CEO and Executive Director to **Executive Chairman**, and Peter Marks moves from Non-Executive Chairman to **Non-Executive Deputy Chairman**.

The changes have been prompted by a strategic decision to start the process of raising the Company's profile and presence in the U.S. including a listing of its securities on the Nasdaq exchange ('**Potential Secondary Listing**'). The Company currently is undertaking the work necessary for this to occur.

The Company regards this strategic decision as a natural progression for it as a developer of a drug candidate with significant commercial and partnering opportunities, with that candidate, Veyonda<sup>®</sup>, due to move into a busy clinical trial program in 2020 in the U.S. As Chairman, Graham will spend a considerable amount of time looking to raise the Company's profile in the U.S. capital markets.

Graham previously led the successful listing on Nasdaq of two companies in 1998 in 2002, both of which remain listed.

Beata Niechoda MB BS, MBA, PhD will join as a Special Advisor to the Board. Beata will bring her extensive experience as a medical director in major pharmaceutical companies in the form of independent advice to the Board on the Company's commercial strategies as an emerging player in the global biotechnology sector.

Graham and Beata will complement the function of Greg van Wyk MB BCh, BBA, MEC as Noxopharm CEO and CMO, whose appointment was announced previously, and together will ensure that the Company has the skills and experience necessary to guide Veyonda<sup>®</sup> through its various clinical phases and to a successful commercial outcome. Greg will be assisted by the appointment of Ms Jeanette Bell BMedSc MScM as Chief Operating Officer.

As a result of the Company's progress and subsequent growth, the Company has brought its accounting functions in-house through the appointment of Mr Shawn Van Boheemen BBus MCom FCPA JP as Chief Financial Officer.

**About Veyonda®**

Veyonda® (previously known as NOX66) is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil. Idronoxil inhibits the oncogene, Ecto-NOX disulfide-thiol exchanger type 2, leading to inhibition of the key secondary pro-survival messenger, sphingosine-1-phosphate. This enhances the DNA-damaging effects of both radiotherapy and cytotoxic chemotherapy, in turn triggering by as a yet to be disclosed up-regulation of the body's innate immune system.

**About Noxopharm**

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney, New York and Hong Kong. The Company has a primary focus on the development of drugs based on a phenolic chemical structure, with Veyonda® the first pipeline product. The pipeline includes a number of other drug candidates for both oncology (within NOX) and non-oncology indications (in subsidiary company, Nyrada Inc).

**Investor & Corporate Enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks  
T: +61 2 9299 9690  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Contact:**

Cherilyn Cecchini, M.D.  
LifeSci Public Relations  
T: +1 646 876 5196  
E: [ccecchini@lifescipublicrelations.com](mailto:ccecchini@lifescipublicrelations.com)

[www.noxopharm.com](http://www.noxopharm.com)

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.